Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 7:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 1,335 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: NaCl-saline placebo Clear all
Terminated Phase 2 Interventional Results available

Botox-A Injection to Improve Bladder Function in Early Spinal Cord Injury (#H-20344)

NCT00711087
View directory record Official record
Conditions
Neurogenic Bladder Dysfunction Nos, Spinal Cord Injury
Interventions
BOTOX-A, Saline injection
Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Oct 11, 2026, 7:34 PM EDT
Completed Phase 1 Interventional

Oxytocin HIV Meth Study

NCT02881177
View directory record Official record
Conditions
Amphetamine Use Disorders
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 11, 2026, 7:34 PM EDT
Recruiting Phase 2 Interventional

Local Anesthesia for Facial Fractures

NCT06429501
View directory record Official record
Conditions
Pain Management
Interventions
Bupivacaine/Epinephrine, Saline
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 11, 2026, 7:34 PM EDT
Withdrawn Phase 3 Interventional

A Randomized, Double-blind, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Against Placebo

NCT02172001
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
Iron isomaltoside 1000, Natrium Chloride 0,9%
Drug
Lead sponsor
Pharmacosmos A/S
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 28, 2016 · Synced Oct 11, 2026, 7:34 PM EDT
Completed Phase 3 Interventional Results available

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Cervical Dystonia

NCT00407030
View directory record Official record
Conditions
Cervical Dystonia
Interventions
incobotulinumtoxinA (Xeomin) (240 Units), incobotulinumtoxinA (Xeomin) (120 Units), Placebo
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2013 · Synced Oct 11, 2026, 7:34 PM EDT
Active, not recruiting Phase 2 Interventional

Study of JK07 in Patients With Chronic Heart Failure

NCT06369298
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
Interventions
JK07, Placebo
Drug
Lead sponsor
Salubris Biotherapeutics Inc
Industry
Eligibility
18 Years to 85 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
51
States / cities
Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 45 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 11, 2026, 7:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Intake and Intra-Nasal Insulin for African American Adults (FIINAAL)

NCT04739371
View directory record Official record
Conditions
Insulin
Interventions
Insulin, Regular, Human, Placebo
Drug
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
45 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Oct 11, 2026, 7:34 PM EDT
Active, not recruiting Phase 3 Interventional

Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury

NCT03992404
View directory record Official record
Conditions
Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury
Interventions
NT 201, Placebo
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years to 85 Years
Enrollment
603 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
15
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 11, 2026, 7:34 PM EDT
Completed Phase 2 Interventional Results available

Prevention of Bone Loss After Acute SCI by Zoledronic Acid

NCT02325414
View directory record Official record
Conditions
Spinal Cord Injury, Acute Spinal Cord Injury, Bone Loss, Osteoporosis
Interventions
Zoledronic acid, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 11, 2026, 7:34 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Use of Tranexamic Acid in Reduction Mammoplasty

NCT04947514
View directory record Official record
Conditions
Hematoma Postoperative, Venous Thromboembolism
Interventions
Tranexamic acid, Placebo (topical saline)
Drug · Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Oct 11, 2026, 7:34 PM EDT
Recruiting Phase 2 Interventional

Efficacy and Safety Study of TPX-115 on Partial-thickness Rotator Cuff Tear

NCT07219654
View directory record Official record
Conditions
Partial Thickness Rotator Cuff Tears
Interventions
TPX-115, Cryopreserving hyaluronic acid medium, Saline
Biological · Other · Drug
Lead sponsor
Tego Science, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
La Mesa, California • Deerfield Beach, Florida • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 11, 2026, 7:34 PM EDT
Completed Phase 2 Interventional

Oxytocin to Enhance Integrated Treatment for AUD and PTSD

NCT04523922
View directory record Official record
Conditions
PTSD, Alcohol Use Disorder
Interventions
40 IU Intranasal Oxytocin, Placebo, Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure
Drug · Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 70 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 11, 2026, 7:34 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Botulinum Toxin is a Potential Prophylactic Therapy for Minimizing Post-excisional Scarring (Allergan Botox Scar Study)

NCT02623829
View directory record Official record
Conditions
Post-operative Excessive Scarring
Interventions
Botulinum Toxin, Saline
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 11, 2026, 7:34 PM EDT
Completed Early Phase 1 Interventional

IV Tranexamic Acid Prior to Hysterectomy

NCT02911831
View directory record Official record
Conditions
Hysterectomy, Blood Loss, Surgical
Interventions
Tranexamic Acid, Sodium Chloride
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Oct 11, 2026, 7:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A MAD Study of TT301/MW189 in Healthy Volunteers

NCT02942771
View directory record Official record
Conditions
Healthy Adult Volunteers
Interventions
0.075mg/kg TT301/MW189, 0.15mg/kg TT301MW189, 0.25mg/kg TT301/MW189, 0.30mg/kg TT301/MW189, Placebo
Drug
Lead sponsor
Linda Van Eldik
Other
Eligibility
18 Years to 50 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Oct 11, 2026, 7:34 PM EDT
Completed Phase 4 Interventional

Tranexamic Acid for Total Knee Arthroscopy

NCT04443920
View directory record Official record
Conditions
Blood Loss, Surgical
Interventions
Tranexamic acid (TXA), Placebo Normal Saline (NS)
Drug
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 11, 2026, 7:34 PM EDT
Terminated Phase 2 Interventional

Evaluation of MST-188 in Acute Lower Limb Ischemia

NCT02093468
View directory record Official record
Conditions
Acute Limb Ischemia
Interventions
MST-188, Saline
Drug
Lead sponsor
Mast Therapeutics, Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
4
States / cities
Little Rock, Arkansas • Tampa, Florida • Brooklyn, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2015 · Synced Oct 11, 2026, 7:34 PM EDT
Completed Not applicable Interventional Results available

Botulinum Toxin Effects on Plantar Ulcer Recurrence

NCT00845897
View directory record Official record
Conditions
Diabetes Mellitus, Peripheral Neuropathy, Plantar Ulcers
Interventions
Botulinum Toxin, Saline
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Not listed
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Oct 11, 2026, 7:34 PM EDT
Completed Phase 3 Interventional Results available

APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis

NCT01960348
View directory record Official record
Conditions
TTR-mediated Amyloidosis, Amyloidosis, Hereditary, Amyloid Neuropathies, Familial, Familial Amyloid Polyneuropathies, Amyloid Neuropathies, Amyloidosis, Hereditary, Transthyretin-Related
Interventions
patisiran (ALN-TTR02), Sterile Normal Saline (0.9% NaCl)
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
13
States / cities
La Mesa, California • Orange, California • Denver, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Oct 11, 2026, 7:34 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Anthrax Vaccine Clinical Trial to Assess Dose Reduction and Route Change

NCT00119067
View directory record Official record
Conditions
Healthy
Interventions
Anthrax Vaccine Adsorbed, Saline injection
Biological
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years to 61 Years
Enrollment
1,564 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2010
U.S. locations
5
States / cities
Birmingham, Alabama • Atlanta, Georgia • Silver Spring, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Oct 11, 2026, 7:34 PM EDT
Terminated Phase 2 Interventional Results available

A Safety and Efficacy Trial of Stannsoporfin in Neonates With Hyperbilirubinemia

NCT00850993
View directory record Official record
Conditions
Hyperbilirubinemia, Neonatal
Interventions
Stannsoporfin, Placebo, PhotoTherapy (as needed)
Drug · Other
Lead sponsor
InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company
Industry
Eligibility
1 Minute to 48 Hours
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
9
States / cities
Colton, California • San Diego, California • Honolulu, Hawaii + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2019 · Synced Oct 11, 2026, 7:34 PM EDT
Completed Phase 2 Interventional Results available

Safety Evaluation of 3K3A-APC in Ischemic Stroke

NCT02222714
View directory record Official record
Conditions
Ischemic Stroke
Interventions
3K3A-APC, Placebo
Biological · Drug
Lead sponsor
ZZ Biotech, LLC
Industry
Eligibility
18 Years to 90 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
15
States / cities
Los Angeles, California • Chicago, Illinois • Kansas City, Kansas + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2018 · Synced Oct 11, 2026, 7:34 PM EDT
Completed Phase 2 Interventional Results available

Preliminary Study of Piclozotan in Patients With Motor Complications Associated With Parkinson's Disease

NCT00623363
View directory record Official record
Conditions
Parkinson's Disease
Interventions
piclozotan, 0.9% sodium chloride (normal saline)
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
40 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
5
States / cities
Fountain Valley, California • Tampa, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Oct 11, 2026, 7:34 PM EDT
Terminated Phase 2 Interventional Results available

The Efficacy Of Intravenous Immunoglobulin Therapy In Treatment Induced Neuropathy Of Diabetes

NCT02915263
View directory record Official record
Conditions
Diabetes Complications, Diabetes Mellitus, Diabetic Neuropathies
Interventions
IGIV-C, 0.9% Sodium Chloride
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 11, 2026, 7:34 PM EDT